MK8722

1394371-71-1

C24H20ClN3O4

DMSO : >= 62.5 mg/mL (138.92 mM)

Epigenetics; PI3K/Akt/mTOR

MK8722 is a potent and systemic pan-AMPK activator. IC50 & Target: AMPK^[1] In Vitro: MK8722 (MK-8722) is a potent, direct, allosteric activator of all 12 mammalian AMPK complexes. MK8722 activates pAMPK complexes with increased potency and magnitude versus AMP, with EC₅₀ values of ca.1 to 60 nM and increased activation by factors of ca.4 to 24. Although MK8722 exhibits higher affinity for beta1-containing (ca.1 to 6 nM) versus beta2-containing (ca.15 to 63 nM) pAMPK complexes, it is the most potent activator of beta2 complexes reported to date. pAMPK activation by maximal AMP plus MK8722 is synergistic, demonstrating that the agents act at distinct sites^[1]. In Vivo: Chronic antihyperglycemic efficacy of MK8722 (MK-8722) is evaluated in db/db mice, a leptin receptor-deficient T2DM model. Once-daily administration of MK8722 results in dose-dependent lowering of ambient blood glucose. On treatment day 12, glucose reductions after MK8722 treatment (30 mpk/day) are comparable to those observed with the PPARgamma agonist BRL49653 (3 mpk/day). Unlike BRL49653, the glucose-lowering action of MK8722 manifests without significant effects on body weight, which is a consistent finding. Dose-dependent increases in tissue pACC are maintained throughout the dosing period. Chronic efficacy, without tachyphylaxis, is also observed in additional dysmetabolic and diabetic rodent models. In all cases, efficacy is associated with trough MK8722 plasma levels comparable to the concentrations required to acutely stimulate skeletal muscle glucose uptake. Chronic MK8722 dosing in mice also increases muscle Glut4 protein levels, possibly contributing to efficacy^[1].